Luvu Brands Inc. (LUVU): Ditto. I think .30 is low. I think we...

Jawesomel · 2021-06-13T20:07:57.0300000Z

Ditto. I think .30 is low. I think we are looking at a $2.00 stock here.

Play Episode

4min

Proactive - Interviews for investors

MP Evans posts record 2024 results, eyes growth

MP Evans Group PLC (AIM:MPE) CEO Matthew Coulson takes Proactive's Stephen Gunnion through the company’s record results for 2024 and the strong start to 2025. MP Evans Group reported a robust financial performance in 2024, with Coulson confirming a record profit and a 66% increase in earnings per share. “It’s been a fantastic year for the group,” Coulson said, noting that high pricing supported the result, with prices averaging around $820 per tonne for the year. The company processed 1.6 million tonnes of crop in 2024, maintaining output despite weather-related challenges in Indonesia. Coulson highlighted this achievement in context: while Indonesia saw a slight national decline in crop yield, MP Evans sustained high volumes, reflecting operational resilience. Planting activity also continued across its operations, particularly in South Sumatra and East Kalimantan. The company expects to exceed 11,000 hectares planted at its Musi Rawas estate in early 2025, while its ABK site in East Kalimantan is set for more extensive development this year. Coulson also noted a milestone in sustainability, with over 250,000 tonnes of certified sustainable output processed across the company’s six mills in 2024. Looking ahead, he said 2025 had started positively, with pricing in the first two months averaging $870 per tonne, and the company is actively exploring acquisition opportunities. Visit Proactive’s YouTube channel for more insightful interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update. #MPEvans #PalmOil #Agribusiness #SustainableFarming #IndonesiaAgriculture #CropProduction #AgricultureInvestment #ESGInvesting #DividendStocks #CommoditiesMarket #ProactiveInvestors

Proactive - Interviews for investors

Thor Explorations says Douta-West discovery adds gold ounces for upcoming PFS

Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) CEO Segun Lawson talked with Proactive's Stephen Gunnion about progress at the Douta gold project in Senegal, with a specific focus on the Douta-West licence. Lawson outlined that Thor acquired the licence a year ago and has since been advancing drilling efforts there. He confirmed the company has now made a fresh discovery, which includes oxide, free-flowing, recoverable gold material. “These are wide intersections between 12 and 20 metres wide, with very good grades between 1.3 and just over 2 grams per ton,” Lawson said. He added that the anomaly runs for approximately two kilometres and could be a significant contributor to the overall economics of the project. Lawson noted that the next step is to fully drill the strike length of the discovery zone. This will allow the company to include the newly identified ounces into its mine plan and potentially enhance the preliminary feasibility study (PFS). He also highlighted that the company is not pursuing exploration for academic purposes, but rather with a clear intent to build and deliver value to shareholders. Lawson confirmed that following the completion of the drilling campaign, Thor will provide an updated timeline for the PFS. Watch the full interview for more insights, and don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for future updates. #ThorExplorations #GoldDiscovery #MiningUpdate #SenegalMining #DrillResults #DoutaProject #GoldStocks #PFS #JuniorMining #ResourceExpansion

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

EnWave expands footprint with commercial license in Japan and U.S. biopharmaceutical agreement

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce the company has signed a commercial license agreement with Hokkai Yamato Foods Japan, a leading producer of processed foods such as soups, furikake, and ochazuke. As part of the agreement, Hokkai Yamato has acquired a 10kW Radiant Energy Vacuum (REV™) machine to drive product development and support early-stage commercial production in Japan. This license grants Hokkai Yamato exclusive rights to use EnWave’s patented REV™ technology for the production of various food products within Japan. In return, Hokkai Yamato will pay royalties to EnWave, consistent with existing licensing agreements. EnWave will work closely with Hokkai Yamato to optimize product development and ensure long-term commercial success. In addition to expanding its presence in the Japanese food sector, EnWave has also signed a master service agreement with BioTechnique, a U.S.-based pharmaceutical contract manufacturer. This agreement lays the groundwork for BioTechnique to evaluate EnWave’s REV™ dehydration technology as a potential alternative to freeze-drying in biopharmaceutical applications. As part of the collaboration, BioTechnique will conduct paid testing of several liquid pharmaceutical products, drying them in vials using pilot-scale REV™ machinery at EnWave’s Innovation Center in Delta, British Columbia. If the results prove successful, BioTechnique may choose to acquire its own REV™ equipment to provide dehydration services directly to its network of leading pharmaceutical clients. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #CEOInterview #Peru #Spain #Blueberry #Snacks #Royalties #TradeMission

Followers	7
Posts	91
Boards Moderated	0
Alias Born	07/10/2015

Volume:	-
Day Range:
Bid:	0.0411
Ask:	0.0587
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

LUVU Detailed Quote

Recent LUVU News

More LUVU News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent LUVU News

Go Ad-Free